Retinal Degeneration Fund

The fund invests exclusively in inherited retinal diseases and dry age-related macular degeneration. Its mandate does not extend to wet AMD, glaucoma, or other ophthalmic indications unless there is a direct mechanistic link to retinal degeneration driven by IRDs or dry AMD pathways.

The vehicle targets the critical gap between late-discovery research and early clinical development. Investments are concentrated at the seed and startup equity stages, where capital is needed to move assets from translational science through preclinical proof-of-concept and into first-in-human studies.

Available public disclosures describe a direct-investment model focused on therapeutic companies and translational assets. There is no mention of fund-of-funds commitments or LP positions in larger biotech venture funds, consistent with a specialized vehicle that deploys capital directly into retinal innovation companies.

The firm is an asset manager structured as a private equity vehicle, not a family office. Its sole investment mandate — retinal degeneration — and its mission-driven orientation suggest it may be capitalized by a philanthropically aligned entity or disease foundation, but the specific capital source is not publicly identified.

The fund does not invest in generalist biotech platforms, non-ophthalmologic therapeutics, or medical devices for non-retinal indications. Its thesis is concentrated entirely on the biology of retinal degeneration, excluding conditions such as glaucoma, cataract, and refractive surgery unless retinal degeneration is the primary disease driver.